Onderneming Algernon Pharmaceuticals Inc.
Aandelen
AGN
CA01559R4008
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,125 CAD | +13,64% | +13,64% | +92,31% |
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chris Moreau
CEO | Chief Executive Officer | 59 | 01-03-18 |
James Kinley
DFI | Director of Finance/CFO | 45 | 01-12-21 |
Chief Operating Officer | 41 | 01-03-21 | |
Ahmad Khalil
CTO | Chief Tech/Sci/R&D Officer | - | 01-03-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Harry Bloomfield
CHM | Chairman | 79 | 08-09-21 |
Chris Moreau
CEO | Chief Executive Officer | 59 | 01-03-18 |
Mark Williams
BRD | Director/Board Member | 52 | 22-09-21 |
James Kinley
DFI | Director of Finance/CFO | 45 | 01-12-21 |
Raj Attariwala
BRD | Director/Board Member | 55 | 26-10-15 |
Howard Gutman
BRD | Director/Board Member | - | 28-02-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 21 840 722 | 21 665 319 ( 99,20 %) | 0 | 99,20 % |
Bedrijfsgegevens
Algernon Pharmaceuticals, Inc.
601 West Broadway Street Suite 400
V5Z 4C2, Vancouver
+604-398-4175
http://www.algernonpharmaceuticals.comSector
Kwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
+92,31% | 2 mln. | |
+3,91% | 109 mld. | |
+10,87% | 105 mld. | |
+1,28% | 22,25 mld. | |
-13,14% | 22,09 mld. | |
-7,05% | 18,68 mld. | |
-38,36% | 17,58 mld. | |
-10,66% | 16,85 mld. | |
+3,75% | 13,76 mld. | |
+36,70% | 12,46 mld. |